Jupiter Topco LLC Makes New $30.62 Million Investment in Enliven Therapeutics, Inc. $ELVN

Key Points

• Jupiter Topco LLC acquired 604,122 Enliven Therapeutics shares worth approximately $30.62 million, giving it a 0.82% stake. Institutional investors collectively own 95.08% of the company.
• Analyst sentiment remains broadly positive, with eight Buy ratings and one Sell rating producing a “Moderate Buy” consensus and an average price target of $75.00.
• Enliven shares opened at $57.86 after falling 4.4%; the company also reported a quarterly loss of $0.49 per share, missing the $0.39-per-share consensus estimate. Meanwhile, insiders have sold about $11.34 million of stock over the past 90 days.

Jupiter Topco LLC acquired a new stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 604,122 shares of the company's stock, valued at approximately $30,617,000. Jupiter Topco LLC owned about 0.82% of Enliven Therapeutics at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the stock. BlackRock Inc. bought a new stake in shares of Enliven Therapeutics during the 2nd quarter worth about $221,255,000. Vestal Point Capital LP grew its stake in Enliven Therapeutics by 230.2% in the 4th quarter. Vestal Point Capital LP now owns 3,830,000 shares of the company's stock valued at $58,982,000 after buying an additional 2,670,000 shares during the last quarter. Siren L.L.C. bought a new position in Enliven Therapeutics in the 1st quarter valued at about $29,252,000. Affinity Asset Advisors LLC bought a new position in Enliven Therapeutics in the 1st quarter valued at about $23,007,000. Finally, TCG Crossover Management LLC acquired a new stake in Enliven Therapeutics during the second quarter worth approximately $9,990,000. 95.08% of the stock is owned by institutional investors.

Analyst Ratings Changes

ELVN has been the subject of a number of research analyst reports. Wall Street Zen cut Enliven Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, August 8th. Stifel Nicolaus lifted their price target on Enliven Therapeutics from $80.00 to $82.00 and gave the stock a "buy" rating in a report on Thursday, August 6th. HC Wainwright boosted their price target on Enliven Therapeutics from $56.00 to $64.00 and gave the company a "buy" rating in a research note on Thursday, July 9th. William Blair assumed coverage on Enliven Therapeutics in a research note on Tuesday, August 18th. They issued an "outperform" rating for the company. Finally, The Goldman Sachs Group upped their price objective on Enliven Therapeutics from $67.00 to $80.00 and gave the company a "buy" rating in a report on Thursday, August 6th. Eight investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $75.00.

Insider Activity at Enliven Therapeutics

In related news, Director Mika K. Derynck sold 158,795 shares of the stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $60.21, for a total transaction of $9,561,046.95. Following the sale, the director owned 87,373 shares of the company's stock, valued at $5,260,728.33. This represents a 64.51% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Lori Anne Kunkel sold 10,000 shares of the firm's stock in a transaction on Monday, July 6th. The stock was sold at an average price of $50.49, for a total value of $504,900.00. Following the transaction, the director owned 41,884 shares in the company, valued at approximately $2,114,723.16. This trade represents a 19.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 196,849 shares of company stock worth $11,344,257. Company insiders own 3.00% of the company's stock.

Enliven Therapeutics Stock Down 4.4%

Shares of Enliven Therapeutics stock opened at $57.86 on Friday. The stock has a market capitalization of $4.24 billion, a price-to-earnings ratio of -34.65 and a beta of 0.27. Enliven Therapeutics, Inc. has a twelve month low of $14.78 and a twelve month high of $62.32. The company has a 50-day simple moving average of $54.62 and a two-hundred day simple moving average of $43.10.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.10). On average, sell-side analysts anticipate that Enliven Therapeutics, Inc. will post -1.69 earnings per share for the current fiscal year.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source